AN1 14.3% 0.8¢ anagenics limited

Ann: AGM Presentation by CEO, page-63

  1. 1,334 Posts.
    lightbulb Created with Sketch. 141
    Lyramid Ltd and KineraLtd would themselves commercialise their IP including Advangen paying either as applicable for its Midkine for its Evolis range. The present "lifeline" would not be severed. Any other funding if required would be on commercial terms. However, the subsidiaries were never meant to bleed Cellmid. Good point Hobbit2233 I hope I've answered.
 
watchlist Created with Sketch. Add AN1 (ASX) to my watchlist
(20min delay)
Last
0.8¢
Change
0.001(14.3%)
Mkt cap ! $3.691M
Open High Low Value Volume
0.8¢ 0.8¢ 0.8¢ $1.92K 240K

Buyers (Bids)

No. Vol. Price($)
3 493225 0.7¢
 

Sellers (Offers)

Price($) Vol. No.
1.0¢ 615000 4
View Market Depth
Last trade - 10.07am 21/06/2024 (20 minute delay) ?
AN1 (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.